Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line de… Read more
Samsung Biologics Co Ltd - Asset Resilience Ratio
Samsung Biologics Co Ltd (207940) has an Asset Resilience Ratio of 5.66% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Samsung Biologics Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Samsung Biologics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.04 Trillion | 5.66% |
| Total Liquid Assets | ₩1.04 Trillion | 5.66% |
Asset Resilience Insights
- Limited Liquidity: Samsung Biologics Co Ltd maintains only 5.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Samsung Biologics Co Ltd Industry Peers by Asset Resilience Ratio
Compare Samsung Biologics Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Samsung Biologics Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Samsung Biologics Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.42% | ₩940.07 Billion | ₩17.34 Trillion | -5.10pp |
| 2023-12-31 | 10.52% | ₩1.69 Trillion | ₩16.05 Trillion | -3.37pp |
| 2022-12-31 | 13.89% | ₩2.30 Trillion | ₩16.58 Trillion | -2.73pp |
| 2021-12-31 | 16.61% | ₩1.32 Trillion | ₩7.97 Trillion | +3.79pp |
| 2020-12-31 | 12.82% | ₩823.60 Billion | ₩6.42 Trillion | +3.27pp |
| 2019-12-31 | 9.55% | ₩564.82 Billion | ₩5.91 Trillion | -9.02pp |
| 2018-12-31 | 18.58% | ₩1.11 Trillion | ₩5.98 Trillion | +18.26pp |
| 2017-12-31 | 0.31% | ₩22.61 Billion | ₩7.18 Trillion | -12.78pp |
| 2016-12-31 | 13.09% | ₩986.29 Billion | ₩7.53 Trillion | -- |